Inovio Pharmaceuticals Inc INO
News
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights
INOVIO Announces Pricing of Approximately $75 Million Public Offering
INOVIO Announces Proposed Public Offering of its Common Stock
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
INOVIO to Participate in Upcoming Scientific Conferences
Inovio Gets Accelerated FDA Approval of Voceryq; Shares More Than Triple After Hours
Stocks to Watch: SVRN, Inovio, Intel
INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
INOVIO to Participate in Upcoming Investor Conferences
Inovio Shares Drop After FDA Says No Plans to Discuss INO-3107 Application

